Formulation of bovine respiratory syncytial virus fusion protein with CpG oligodeoxynucleotide, cationic host defence peptide and polyphosphazene enhances humoral and cellular responses and induces a protective type 1 immune response in mice

Journal of General Virology

Volumn 90, Issue 8, 2009, Pages 1892-1905

  Kovacs Nolan, J ^a   Mapletoft, J W ^a   Lawman, Z ^a   Babiuk, L A ^b   van Drunen Littel van den Hurk, Sylvia ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BOVINE RESPIRATORY SYNCYTIAL VIRUS CPG OLIGODEOXYNUCLEOTIDE FUSION PROTEIN; GAMMA INTERFERON; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; INDOLICIDIN; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 5; P[OLYPHOSPHAZENE; POLYMER; RESPIRATORY SYNCYTIAL VIRUS VACCINE; UNCLASSIFIED DRUG; ANTIMICROBIAL CATIONIC PEPTIDE; CPG OLIGONUCLEOTIDE; CPG-OLIGONUCLEOTIDE; CYTOKINE; IMMUNOLOGICAL ADJUVANT; OLIGODEOXYRIBONUCLEOTIDE; ORGANOPHOSPHORUS COMPOUND; POLY(PHOSPHAZENE); VIRUS ANTIBODY; VIRUS FUSION PROTEIN;

ANIMAL EXPERIMENT; ANTIBODY TITER; ANTIGEN SPECIFICITY; ARTICLE; BAGG ALBINO MOUSE; C57BL 6 MOUSE; CELL STIMULATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; FEMALE; HOST RESISTANCE; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNOGLOBULIN BLOOD LEVEL; MOUSE; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; SPLEEN CELL; TH1 CELL; VIRAL RESPIRATORY TRACT INFECTION; ANIMAL; BLOOD; C57BL MOUSE; IMMUNOLOGY; LUNG; MONONUCLEAR CELL; SECRETION; SERODIAGNOSIS; SPLEEN;

BOVINE RESPIRATORY SYNCYTIAL VIRUS; HUMAN RESPIRATORY SYNCYTIAL VIRUS; MUS; RESPIRATORY SYNCYTIAL VIRUS; RICE STRIPE VIRUS;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, VIRAL; ANTIMICROBIAL CATIONIC PEPTIDES; CYTOKINES; IMMUNOGLOBULIN G; LEUKOCYTES, MONONUCLEAR; LUNG; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NEUTRALIZATION TESTS; OLIGODEOXYRIBONUCLEOTIDES; ORGANOPHOSPHORUS COMPOUNDS; POLYMERS; RESPIRATORY SYNCYTIAL VIRUS, BOVINE; SPLEEN; VIRAL FUSION PROTEINS;

EID: 69449101292     PISSN: 00221317     EISSN: 14652099     Source Type: Journal    
DOI: 10.1099/vir.0.011684-0     Document Type: Article

References (68)

1. + T cells. Clin Exp Immunol 88, 527-536.
2. J6-1 DNA vaccine. Leuk Res 29, 535-543.
3. Andrianov, A. K., Svirkin, Y. Y. & LeGolvan, M. P. (2004). Synthesis and biologically relevant properties of polyphosphazene polyacids. Biomacromolecules 5, 1999-2006.
4. Andrianov, A. K., Marin, A. & Roberts, B. E. (2005). Polyphosphazene polyelectrolytes: a link between the formation of noncovalent complexes with antigenic proteins and immunostimulating activity. Biomacromolecules 6, 1375-1379.
5. Antonis, A. F., Schrijver, R. S., Daus, F., Steverink, P. J., Stockhofe, N., Hensen, E. J., Langedijk, J. P. & Van Der Most, R. G. (2003). Vaccine-induced immunopathology during bovine respiratory syncytial virus infection: exploring the parameters of pathogenesis. J Virol 77, 12067-12073.
6. Baca-Estrada, M. E., Snider, M., Tikoo, S. K., Harland, R., Babiuk, L. A. & van Drunen Littel-van den Hurk, S. (1996). Immunogenicity of bovine herpesvirus 1 glycoprotein D in mice: effect of antigen form on the induction of cellular and humoral immune responses. Viral Immunol 9, 11-22.
7. Bangham, C. R., Openshaw, P. J., Ball, L. A., King, A. M., Wertz, G. W. & Askonas, B. A. (1986). Human and murine cytotoxic T cells specific to respiratory syncytial virus recognize the viral nucleoprotein (N), but not the major glycoprotein (G), expressed by vaccinia virus recombinants. J Immunol 137, 3973-3977.
8. Bowdish, D. M., Davidson, D. J., Scott, M. G. & Hancock, R. E. (2005). Immunomodulatory activities of small host defense peptides. Antimicrob Agents Chemother 49, 1727-1732.
9. Brown, K. L. & Hancock, R. E. (2006). Cationic host defense (antimicrobial) peptides. Curr Opin Immunol 18, 24-30.
10. Cannon, M. J., Openshaw, P. J. & Askonas, B. A. (1988). Cytotoxic T cells clear virus but augment lung pathology in mice infected with respiratory syncytial virus. J Exp Med 168, 1163-1168.
11. Castilow, E. M., Meyerholz, D. K. & Varga, S. M. (2008). IL-13 is required for eosinophil entry into the lung during respiratory syncytial virus vaccine-enhanced disease. J Immunol 180, 2376-2384.
12. Collins, P. L. & Crowe, J. E., Jr (2007). Respiratory syncytial virus and metapneumovirus. In Fields Virology, 5th edn, vol. 2, p. 1601. Edited by D. M. Knipe & P. M. Howley. Philadelphia: Lippincott Williams & Wilkins.
13. Collins, P. L., Huang, Y. T. & Wertz, G. W. (1984). Nucleotide sequence of the gene encoding the fusion (F) glycoprotein of human respiratory syncytial virus. Proc Natl Acad Sci U S A 81, 7683-7687.
14. Davis, H. L., Weeratna, R., Waldschmidt, T. J., Tygrett, L., Schorr, J. & Krieg, A. M. (1998). CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. J Immunol 160, 870-876.
15. Delgado, M. F., Coviello, S., Monsalvo, A. C., Melendi, G. A., Hernandez, J. Z., Batalle, J. P., Diaz, L., Trento, A., Chang, H. Y. & other authors (2009). Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. Nat Med 15, 34-41.
16. de Waal, L., Suzer, Y., Wyatt, L. S., Sintnicolaas, K., Sutter, G., Moss, B., Osterhaus, A. D. & de Swart, R. L. (2006). T cell responses to respiratory syncytial virus fusion and attachment proteins in human peripheral blood mononuclear cells. Viral Immunol 19, 669-678.
17. Durbin, J. E., Johnson, T. R., Durbin, R. K., Mertz, S. E., Morotti, R. A., Peebles, R. S. & Graham, B. S. (2002). The role of IFN in respiratory syncytial virus pathogenesis. J Immunol 168, 2944-2952.
18. Fenton, C., Scott, L. J. & Plosker, G. L. (2004). Palivizumab: a review of its use as prophylaxis for serious respiratory syncytial virus infection. Paediatr Drugs 6, 177-197.
19. Fritz, J. H., Brunner, S., Birnstiel, M. L., Buschle, M., Gabain, A., Mattner, F. & Zauner, W. (2004). The artificial antimicrobial peptide KLKLLLLLKLK induces predominantly a Th2-type immune response to co-injected antigens. Vaccine 22, 3274-3284.
20. Gershwin, L. J. (2007). Bovine respiratory syncytial virus infection: immunopathogenic mechanisms. Anim Health Res Rev 8, 207-213.
21. Glezen, W. P., Taber, L. H., Frank, A. L. & Kasel, J. A. (1986). Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child 140, 543-546.
22. Graham, B. S., Johnson, T. R. & Peebles, R. S. (2000). Immune-mediated disease pathogenesis in respiratory syncytial virus infection. Immunopharmacology 48, 237-247.
23. Hall, C. B., Walsh, E. E., Long, C. E. & Schnabel, K. C. (1991). Immunity to and frequency of reinfection with respiratory syncytial virus. J Infect Dis 163, 693-698.
24. Hancock, R. E. (2001). Cationic peptides: effectors in innate immunity and novel antimicrobials. Lancet Infect Dis 1, 156-164.
25. Hancock, G. E., Hahn, D. J., Speelman, D. J., Hildreth, S. W., Pillai, S. & McQueen, K. (1994). The pulmonary immune response of BALB/c mice vaccinated with the fusion protein of respiratory syncytial virus. Vaccine 12, 267-274.
26. Hancock, G. E., Speelman, D. J., Frenchick, P. J., Mineo-Kuhn, M. M., Baggs, R. B. & Hahn, D. J. (1995). Formulation of the purified fusion protein of respiratory syncytial virus with the saponin QS-21 induces protective immune responses in BALB/c mice that are similar to those generated by experimental infection. Vaccine 13, 391-400.
27. Hancock, G. E., Heers, K. M., Smith, J. D., Scheuer, C. A., Ibraghimov, A. R. & Pryharski, K. S. (2001). CpG containing oligodeoxynucleotides are potent adjuvants for parenteral vaccination with the fusion (F) protein of respiratory syncytial virus (RSV). Vaccine 19, 4874-4882.
28. Ioannou, X. P., Gomis, S. M., Karvonen, B., Hecker, R., Babiuk, L. A. & van Drunen Littel-van den Hurk, S. (2002). CpG-containing oligodeoxynucleotides, in combination with conventional adjuvants, enhance the magnitude and change the bias of the immune responses to a herpesvirus glycoprotein. Vaccine 21, 127-137.
29. Isaacs, D. (1991). Viral subunit vaccines. Lancet 337, 1223-1224.
30. Johnson, P. R. & Collins, P. L. (1988). The fusion glycoproteins of human respiratory syncytial virus of subgroups A and B: sequence conservation provides a structural basis for antigenic relatedness. J Gen Virol 69, 2623-2628.
31. Johnson, T. R., Parker, R. A., Johnson, J. E. & Graham, B. S. (2003). IL-13 is sufficient for respiratory syncytial virus G glycoprotein-induced eosinophilia after respiratory syncytial virus challenge. J Immunol 170, 2037-2045.
32. Klinman, D. M. (2004). Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat Rev Immunol 4, 249-258.
33. Klinman, D. M., Yi, A. K., Beaucage, S. L., Conover, J. & Krieg, A. M. (1996). CpG motifs present in bacterial DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon γ. Proc Natl Acad Sci U S A 93, 2879-2883.
34. Klinman, D. M., Barnhart, K. M. & Conover, J. (1999). CpG motifs as immune adjuvants. Vaccine 17, 19-25.
35. Kovacs-Nolan, J., Latimer, L., Landi, A., Jenssen, H., Hancock, R. E. W., Babiuk, L. A. & van Drunen Littel-van den Hurk, S. (2009). The novel adjuvant combination of CpG ODN, indolicidin and polyphosphazene induces potent antibody- and cell-mediated immune responses in mice. Vaccine 27, 2055-2064.
36. Krieg, A. M. (2006). Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov 5, 471-484.
37. Krieg, A. M., Yi, A. K., Matson, S., Waldschmidt, T. J., Bishop, G. A., Teasdale, R., Koretzky, G. A. & Klinman, D. M. (1995). CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374, 546-549.
38. Kurosaka, K., Chen, Q., Yarovinsky, F., Oppenheim, J. J. & Yang, D. (2005). Mouse cathelin-related antimicrobial peptide chemoattracts leukocytes using formyl peptide receptor-like 1/mouse formyl peptide receptor-like 2 as the receptor and acts as an immune adjuvant. J Immunol 174, 6257-6265.
39. Laemmli, U. K. (1970). Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227, 680-685.
40. Lingnau, K., Egyed, A., Schellack, C., Mattner, F., Buschle, M. & Schmidt, W. (2002). Poly-L-arginine synergizes with oligodeoxy-nucleotides containing CpG-motifs (CpG-ODN) for enhanced and prolonged immune responses and prevents the CpG-ODN-induced systemic release of pro-inflammatory cytokines. Vaccine 20, 3498-3508.
41. Lopez, J. A., Bustos, R., Orvell, C., Berois, M., Arbiza, J., Garcia-Barreno, B. & Melero, J. A. (1998). Antigenic structure of human respiratory syncytial virus fusion glycoprotein. J Virol 72, 6922-6928.
42. Mapletoft, J. W., Oumouna,M., Kovacs-Nolan, J., Latimer, L., Mutwiri, G., Babiuk, L. A. & van Drunen Littel-van den Hurk, S. (2008). Intranasal immunization of mice with a formalin-inactivated bovine respiratory syncytial virus vaccine co-formulated with CpG oligodeoxynucleotides and polyphosphazenes results in enhanced protection. J Gen Virol 89, 250-260.
43. McCluskie, M. J. & Krieg, A. M. (2006). Enhancement of infectious disease vaccines through TLR9-dependent recognition of CpG DNA. Curr Top Microbiol Immunol 311, 155-178.
44. McNeal, M. M., Rae, M. N. & Ward, R. L. (1999). Effects of different adjuvants on rotavirus antibody responses and protection in mice following intramuscular immunization with inactivated rotavirus. Vaccine 17, 1573-1580.
45. Meyer, G., Deplanche, M. & Schelcher, F. (2008). Human and bovine respiratory syncytial virus vaccine research and development. Comp Immunol Microbiol Infect Dis 31, 191-225.
46. Muelenaer, P. M., Henderson, F. W., Hemming, V. G., Walsh, E. E., Anderson, L. J., Prince, G. A. & Murphy, B. R. (1991). Group-specific serum antibody responses in children with primary and recurrent respiratory syncytial virus infections. J Infect Dis 164, 15-21.
47. Mutwiri, G., Benjamin, P., Soita, H., Townsend, H., Yost, R., Roberts, B., Andrianov, A. K. & Babiuk, L. A. (2007). Poly[di(sodium carboxylatoethylphenoxy)phosphazene] (PCEP) is a potent enhancer of mixed Th1/Th2 immune responses in mice immunized with influenza virus antigens. Vaccine 25, 1204-1213.
48. Palframan, R. T., Collins, P. D., Williams, T. J. & Rankin, S. M. (1998). Eotaxin induces a rapid release of eosinophils and their progenitors from the bone marrow. Blood 91, 2240-2248.
49. Payne, L. G. & Andrianov, A. K. (1998). Protein release from polyphosphazene matrices. Adv Drug Deliv Rev 31, 185-196.
50. Payne, L. G., Jenkins, S. A., Woods, A. L., Grund, E. M., Geribo, W. E., Loebelenz, J. R., Andrianov, A. K. & Roberts, B. E. (1998). Poly[di(carboxylatophenoxy)phosphazene] (PCPP) is a potent immunoadjuvant for an influenza vaccine. Vaccine 16, 92-98.
51. Perrie, Y., Mohammed, A. R., Kirby, D. J., McNeil, S. E. & Bramwell, V. W. (2008). Vaccine adjuvant systems: enhancing the efficacy of subunit protein antigens. Int J Pharm 364, 272-280.
52. Polack, F. P., Teng, M. N., Collins, P. L., Prince, G. A., Exner, M., Regele, H., Lirman, D. D., Rabold, R., Hoffman, S. J. & other authors (2002). A role for immune complexes in enhanced respiratory syncytial virus disease. J Exp Med 196, 859-865.
53. Prince, G. A., Mond, J. J., Porter, D. D., Yim, K. C., Lan, S. J. & Klinman, D. M. (2003). Immunoprotective activity and safety of a respiratory syncytial virus vaccine: mucosal delivery of fusion glycoprotein with a CpG oligodeoxynucleotide adjuvant. J Virol 77, 13156-13160.
54. Rankin, S. M., Conroy, D. M. & Williams, T. J. (2000). Eotaxin and eosinophil recruitment: implications for human disease. Mol Med Today 6, 20-27.
55. Selsted, M. E., Novotny, M. J., Morris, W. L., Tang, Y. Q., Smith, W. & Cullor, J. S. (1992). Indolicidin, a novel bactericidal tridecapeptide amide from neutrophils. J Biol Chem 267, 4292-4295.
56. Shay, D. K., Holman, R. C., Newman, R. D., Liu, L. L., Stout, J. W. & Anderson, L. J. (1999). Bronchiolitis-associated hospitalizations among US children, 1980-1996. JAMA 282, 1440-1446.
57. Sigurs, N., Bjarnason, R., Sigurbergsson, F., Kjellman, B. & Bjorksten, B. (1995). Asthma and immunoglobulin E antibodies after respiratory syncytial virus bronchiolitis: a prospective cohort study with matched controls. Pediatrics 95, 500-505.
58. Sigurs, N., Bjarnason, R., Sigurbergsson, F. & Kjellman, B. (2000). Respiratory syncytial virus bronchiolitis in infancy is an important risk factor for asthma and allergy at age 7. Am J Respir Crit Care Med 161, 1501-1507.
59. + T lymphocytes downregulate T helper cell type 2 cytokine secretion and pulmonary eosinophilia during experimental murine respiratory syncytial virus infection. J Exp Med 186, 421-432.
60. Taylor, G., Stott, E. J., Bew, M., Fernie, B. F., Cote, P. J., Collins, A. P., Hughes, M. & Jebbett, J. (1984). Monoclonal antibodies protect against respiratory syncytial virus infection in mice. Immunology 52, 137-142.
61. Valarcher, J. F. & Taylor, G. (2007). Bovine respiratory syncytial virus infection. Vet Res 38, 153-180.
62. Van der Poel, W. H., Brand, A., Kramps, J. A. & Van Oirschot, J. T. (1994). Respiratory syncytial virus infections in human beings and in cattle. J Infect 29, 215-228.
63. Viuff, B., Tjornehoj, K., Larsen, L. E., Rontved, C. M., Uttenthal, A., Ronsholt, L. & Alexandersen, S. (2002). Replication and clearance of respiratory syncytial virus: apoptosis is an important pathway of virus clearance after experimental infection with bovine respiratory syncytial virus. Am J Pathol 161, 2195-2207.
64. Walsh, E. E. (1994). Humoral, mucosal, and cellular immune response to topical immunization with a subunit respiratory syncytial virus vaccine. J Infect Dis 170, 345-350.
65. Walsh, E. E., Schlesinger, J. J. & Brandriss, M. W. (1984). Protection from respiratory syncytial virus infection in cotton rats by passive transfer of monoclonal antibodies. Infect Immun 43, 756-758.
66. Waris, M. E., Tsou, C., Erdman, D. D., Zaki, S. R. & Anderson, L. J. (1996). Respiratory syncytial virus infection in BALB/c mice previously immunized with formalin-inactivated virus induces enhanced pulmonary inflammatory response with a predominant Th2-like cytokine pattern. J Virol 70, 2852-2860.
67. Wu, J. Y., Wade, W. F. & Taylor, R. K. (2001). Evaluation of cholera vaccines formulated with toxin-coregulated pilin peptide plus polymer adjuvant in mice. Infect Immun 69, 7695-7702.
68. Zimmer, G., Conzelmann, K. K. & Herrler, G. (2002). Cleavage at the furin consensus sequence RAR/KR(109) and presence of the intervening peptide of the respiratory syncytial virus fusion protein are dispensable for virus replication in cell culture. J Virol 76, 9218-9224.